Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 2

Effects of short-term (7 days) empagliflozin administration on non-fasting blood glucose (A), 24 hr-urinary glucose excretion (B), 24 hr-urine volume (C) and 24 hr-urinary sodium excretion (D) in db/db mice. Twenty four-hour urine of each mouse was collected with metabolic cages every day before and throughout the experiment. Abbreviations used: UGE, urinary glucose excretion; control, control (untreated) db/db mice; Empa, empagliflozin-treated db/db mice; pre, the data obtained before start of drug treatment. *p < 0.05, †p < 0.01 vs control db/db mice. Values are mean ± SEM (n = 10-11).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840